
MXCT
MaxCyte Inc.
Company Overview
| Mkt Cap | $162.04M | Price | $1.67 |
| Volume | 532.07K | Change | +2.45% |
| P/E Ratio | -3.9 | Open | $1.63 |
| Revenue | $38.6M | Prev Close | $1.63 |
| Net Income | $-41.1M | 52W Range | $1.26 - $5.20 |
| Div Yield | N/A | Target | $7.00 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About MaxCyte Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MXCT | $1.67 | +2.5% | 532.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |